Eton Q3 Sales $57.9M, Up 158%; 2026 Revenue Guidance Raised to >$175M
ETON has more than doubled off its 52-week low of $14.27.
Summary
Eton reported record Q3 2026 product sales of $57.9 million, up 158% year-over-year, with adjusted EBITDA of $28.5 million (49% margin), and raised 2026 revenue guidance to more than $175 million from more than $145 million.
Key Events · Earnings and Guidance · ETON
-
Record Q3 Sales of $57.9M
Third quarter 2026 product sales rose 158% to $57.9 million from $22.5 million a year earlier, driven by the HEMANGEOL addition and growth across INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, DESMODA and Carglumic Acid.
-
Guidance Raised on Revenue and Margin
2026 revenue guidance moves to more than $175 million from more than $145 million, and the adjusted EBITDA margin target to at least 40% from at least 35%.
-
GAAP EPS Inflated by Tax Benefit
GAAP diluted EPS of $1.06 includes a $12.9 million non-cash release of a deferred tax valuation allowance; non-GAAP diluted EPS was $0.50 and adjusted EBITDA $28.5 million, or 49% of revenue.
-
Cash Build to $55.6M
Cash and cash equivalents reached $55.6 million at September 30, 2026, with $49.9 million of net cash from operating activities over the first nine months.
Analysis · ETON · Life Sciences
Eton's third quarter blew past the pace it set in Q2: product sales of $57.9 million versus $22.5 million a year earlier, and adjusted EBITDA of $28.5 million, a 49% margin against 13% a year ago. Management raised full-year revenue guidance to more than $175 million from more than $145 million and lifted the adjusted EBITDA margin target to at least 40% from at least 35%, so growth is arriving with margin expansion rather than being bought with spending. Headline GAAP EPS of $1.06 is flattered by a $12.9 million non-cash release of a deferred tax valuation allowance; the non-GAAP figure of $0.50 per diluted share is the cleaner read on operating performance. Cash stood at $55.6 million, with $49.9 million generated from operations over nine months, so the balance sheet is no longer the constraint it once was. The main caveats are execution-dependent pipeline items: the KHINDIVI label expansion has a May 28, 2027 PDUFA date, LIBERVANT an NDA under review with a March 29, 2027 PDUFA date, and the ET-700 pilot showed better tolerability but weaker copper blocking than GALZIN, pushing faster-release formulations into 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ETON was trading at $56.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $14.27 to $66.37. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.